Datta Pradip, Dasgupta Amitava
Bayer Diagnostics, Tarrytown, NY, USA.
Ther Drug Monit. 2004 Feb;26(1):85-9. doi: 10.1097/00007691-200402000-00016.
Endogenous digoxin-like immunoreactive factors (DLIF) cross-react with antidigoxin antibody and falsely elevate or lower measured serum digoxin concentrations, depending on the assay design. Recently, Bayer Diagnostics released a turbidimetric assay for digoxin on the ADVIA 1650 analyzer. We studied potential interference of DLIF with this new digoxin assay. We analyzed 40 serum specimens from patients who have pathologic conditions that may increase serum DLIF concentrations. These patients were never exposed to digoxin or other agents that may lead to a measurable digoxin concentration. We also analyzed five specimens from autopsy and five specimens from neonates. Apparent digoxin concentrations were measured using the new turbidimetric digoxin assay, the fluorescence polarization immunoassay (FPIA, Abbott Laboratories, Abbott Park, IL), and also the chemiluminescent immunoassay (CLIA, Bayer Diagnostics). We observed measurable apparent digoxin levels with the FPIA in 5 uremic patients (range 0.24-0.86 ng/mL), 6 patients with liver disease (range 0.21-0.72 ng/mL), in 3 patients in the third trimester of pregnancy (0.21-26 ng/mL), and in 3 neonates (range 0.21-0.46 ng/mL). Four out of 5 autopsy specimens showed measurable apparent digoxin concentrations (0.23-0.81 ng/mL). In contrast, only 1 specimen (a uremic patient) showed an apparent digoxin concentration of 0.26 ng/mL with the turbidimetric digoxin immunoassay (FPIA value 0.86 ng/mL, CLIA value 0.32 ng/mL). Because DLIF is absent in the protein-free ultrafiltrate, we also measured free digoxin concentrations in DLIF-positive patients to ensure that the apparent digoxin concentrations were caused by DLIF. We observed no apparent digoxin concentrations in the protein-free ultrafiltrate in any DLIF-positive specimens. When serum specimens containing elevated concentrations of DLIF but no digoxin were supplemented with a known concentration of digoxin, we observed falsely elevated digoxin concentrations by the FPIA, as expected. In contrast, we observed a good agreement between the target and observed concentrations when the new turbidimetric assay was used. We conclude that DLIF has minimal effect on serum digoxin measurements by the new turbidimetric assay.
内源性地高辛样免疫反应因子(DLIF)与抗地高辛抗体发生交叉反应,根据检测设计,会错误地升高或降低所测血清地高辛浓度。最近,拜耳诊断公司在ADVIA 1650分析仪上推出了一种用于检测地高辛的比浊法。我们研究了DLIF对这种新的地高辛检测方法的潜在干扰。我们分析了40份来自可能使血清DLIF浓度升高的病理状况患者的血清标本。这些患者从未接触过地高辛或其他可能导致可测地高辛浓度的药物。我们还分析了5份尸检标本和5份新生儿标本。使用新的比浊法地高辛检测、荧光偏振免疫分析法(FPIA,雅培实验室,伊利诺伊州雅培公园)以及化学发光免疫分析法(CLIA,拜耳诊断公司)测量表观地高辛浓度。我们观察到,在5名尿毒症患者(范围为0.24 - 0.86 ng/mL)、6名肝病患者(范围为0.21 - 0.72 ng/mL)、3名妊娠晚期患者(0.21 - 26 ng/mL)以及3名新生儿(范围为b0.21 - 0.46 ng/mL)中,FPIA检测到可测的表观地高辛水平。5份尸检标本中有4份显示可测的表观地高辛浓度(0.23 - 0.81 ng/mL)。相比之下,比浊法地高辛免疫分析中只有1份标本(一名尿毒症患者)显示表观地高辛浓度为0.26 ng/mL(FPIA值为0.86 ng/mL,CLIA值为0.32 ng/mL)。由于无蛋白超滤液中不存在DLIF,我们还测量了DLIF阳性患者的游离地高辛浓度,以确保表观地高辛浓度是由DLIF引起的。在任何DLIF阳性标本的无蛋白超滤液中,我们均未观察到表观地高辛浓度。当向含有高浓度DLIF但无地高辛的血清标本中添加已知浓度的地高辛时,正如预期的那样,我们观察到FPIA检测到地高辛浓度错误升高。相比之下,使用新的比浊法检测时,我们观察到目标浓度与实测浓度之间具有良好的一致性。我们得出结论,DLIF对新的比浊法检测血清地高辛的影响极小。